<?xml encoding="utf-8" ?> Geron GERN reported third-quarter financial results on Wednesday. The transcript from the company’s ...
SVP, Investor Relations and Corporate Affairs - Dawn Schottlandt Chief Executive Officer - Harout Semerjian Chief Commercial Officer - Ahmed ElNawawi Executive Vice President of Research and ...
Geron achieved FDA approval for RYTELO in June 2024, targeting lower-risk myelodysplastic syndromes. Read what makes GERN ...
FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today ...
Stock forecast & analyst price target predictions based on 4 analysts offering 12-month price targets for GERN in the last 3 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results